Dr. Paul McKenzie was appointed Chief Executive Officer and Managing Director of CSL on 6 March 2023.
Dr. McKenzie has more than 30 years of leadership experience in the global biotechnology industry, including managing complex organisations through compelling growth and transformation.
After joining CSL as Chief Operating Officer in 2019, Dr. McKenzie became accountable for optimising CSL's operations as well as growing the CSL Seqirus, CSL Plasma, and CSL Vifor businesses. He transformed CSL's global end-to-end operations, advanced CSL Seqirus' differentiated portfolio strategy, and led CSL Plasma through COVID-19 challenges while surpassing plasma collection volumes beyond pre-pandemic levels.
Prior to joining CSL, Dr. McKenzie was Executive Vice President of Pharmaceutical Operations & Technology at Biogen. He also served in a range of progressively senior level roles in R&D and manufacturing at Johnson & Johnson, Bristol-Myers Squibb and Merck.
Dr. McKenzie was elected to the U.S. National Academy of Engineering in 2020. He has served on numerous professional and academic boards, most recently the Board of Trustees on the Illinois Institute of Technology and the Society for Biological Engineering. Dr. McKenzie holds a B.S. in Chemical Engineering from the University of Pennsylvania and a Ph.D. in Chemical Engineering from Carnegie Mellon University.
Dr. Paul McKenzie
Chief Executive Officer and Managing Director
